ReviewDrugs2020
New and Emerging Therapies for Alopecia Areata.
Review in Drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Enhancing hair regrowth in Alopecia areata: the power duo of CO2 fractional laser and Bimatoprost.Archives of dermatological research · 2025Trial
- Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study.Dermatology and therapy · 2026Article
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
- Upadacitinib for Alopecia: Current Evidence and Clinical Insights.Skin appendage disorders · 2025Review
- The Role of Mesenchymal Stem Cell-Derived Exosomes in Skin Regeneration, Tissue Repair, and the Regulation of Hair Follicle Growth.Advances in experimental medicine and biology · 2025Review
- A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database.The Journal of dermatology · 2024Article
- Paediatric alopecia areata cases in a tertiary institution in Singapore: a retrospective review.Singapore medical journal · 2024Article
- Growth Factors and Microneedling in Alopecia Areata: A Narrative Review.Skin appendage disorders · 2024Review
- Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey.Clinical, cosmetic and investigational dermatology · 2024Article
- The Roles of Exosomes in Regulating Hair Follicle Growth.Clinical, cosmetic and investigational dermatology · 2024Review
- Review
- Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata.International journal of molecular sciences · 2023Article
- Interleukin-15 and Tumor Necrosis Factor-Dermatology research and practice · 2023Article
- Efficacy and safety of baricitinib in patients with refractory alopecia areata.Dermatologic therapy · 2022Article
- Article
- Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.Nature reviews. Rheumatology · 2022Review
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study.Frontiers in medicine · 2022Article
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.Clinical reviews in allergy & immunology · 2021Review
- Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia areata (AA) is an autoimmune condition that affects up to 2% of the general population. Currently available treatment options for AA are of limited efficacy and can be associated with adverse effects. The advancement in understanding of the genetic and molecular mechanisms of AA has led to the development of novel treatment options, with the Janus kinase (JAK) inhibitor class of drugs at the forefront of ongoing clinical trials. Platelet-rich plasma, fecal transplants, and cytokine-targeted therapy with ustekinumab and dupilumab have also been shown to regrow hair in patients with AA in individual case reports or small studies. Several other novel therapies have preliminary data or are being tested in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.